anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 15,391-15,420
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

15,391-15,420 of 18,554

filter-aware
163
Uses a specific analogy to biotech (Phase 3 success vs. rodent data) to frame the technical limitation as a deceptive practice.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
164
The slide uses an external industry standard (Joule Battery Checklist) as a benchmark to critique the target company's lack of transparency.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
165
Uses a 'The Conversation' article as a diagnostic framework to critique the subject company.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
166
The slide uses a series of news headlines to build a pattern of recurring fraud in the battery sector.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
168
Includes a screenshot of a tweet by Vinod Khosla and a quote from Barron's to illustrate the 'celebrity endorsement' and hype.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
169
Uses external press citations to undermine the credibility of the target company's investors.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
170
Uses a 'villain' narrative technique to undermine investor credibility.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
171
The slide uses a red arrow to connect a redacted excerpt from a lawsuit complaint directly to key takeaways about the fraud allegations.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
176
Uses a 'guilt by association' rhetorical strategy to cast doubt on the target company.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
179
Uses SEC filing excerpts and a Notice of Effectiveness screenshot as evidence of insider dumping.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
05
The slide presents anecdotal evidence of medical side effects to support an activist narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
07
The slide uses a screenshot of a Facebook post to undermine the clinical trial results of the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
12
Uses social media screenshots as primary evidence to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
14
The slide uses a specific social media post as a case study to infer broader safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
18
The slide uses a Q&A format to build a case for the 'two-hit' hypothesis regarding drug interactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
21
The slide uses a direct quote from the Pediatric Endocrine Society guidelines to expose the company's failure to address known side effects in their trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
22
The slide uses a direct quote from a medical paper to expose the ineffectiveness of the company's recommended treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
23
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the context of PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
26
The slide uses anecdotal evidence from online discussion groups to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
27
The slide uses screenshots of Facebook group discussions to provide anecdotal evidence of adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
28
The slide uses screenshots of Facebook group posts as primary evidence of adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
01
Slide 1
This is a regulatory filing document (Citizen Petition) formatted as a letter.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Attention1 hit
02
This is a text-heavy regulatory filing document, likely part of a petition to the FDA regarding safety concerns.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
03
This appears to be a page from a regulatory filing or activist short report, focusing on adverse event reporting and potential obfuscation by the manufacturer.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
04
This slide functions as a legal/regulatory petition argument, using evidence-based reasoning to refute the adequacy of current safety warnings.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
05
The slide is a text-heavy regulatory filing page, likely part of a petition or formal complaint. It uses numbered points to build a case of scientific misconduct.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
06
This appears to be a page from an activist short report or regulatory challenge document.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Desire1 hit